WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201794
Description: Rabusertib, also known as LY2603618, is a n inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.
MedKoo Cat#: 201794
Name: Rabusertib (LY2603618)
Chemical Formula: C18H22BrN5O3
Exact Mass: 435.0906
Molecular Weight: 436.3
Elemental Analysis: C, 49.55; H, 5.08; Br, 18.31; N, 16.05; O, 11.00
Synonym: LY2603618; LY 2603618; LY-2603618; Rabusertib
IUPAC/Chemical Name: (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea.
InChi Key: SYYBDNPGDKKJDU-ZDUSSCGKSA-N
InChi Code: InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
SMILES Code: CC1=C(Br)C=C(C(OC[C@@H]2CNCCO2)=C1)NC(NC3=NC=C(N=C3)C)=O
Appearance: White to off-white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 436.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Compositions of Chk1 kinase inhibitor for cancer treatment By Colvin, Anita A.; Koppenol, Sandy; Wisdom, Wendy A. From PCT Int. Appl. (2008), WO 2008067027 A2 20080605.